In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

STADA Arzneimittel AG

https://www.stada.com/

Latest From STADA Arzneimittel AG

Stada Recruits Ex-Sandoz Exec To Help Steer Biosimilars

Stada has announced the appointment of former Sandoz executive Christine Berndt as head of global development for specialty and biosimilar products, replacing Michael Mack.

Executive Changes Biosimilars

Who’s Hired? Carbogen Amcis Appoints New CEO

Carbogen, Advanz and Perrigo have all announced significant changes to their C-suite staff, while several firms have announced changes to their executive and advisory boards.

Executive Changes Strategy

Stada Gears Up For Higher-Strength Adalimumab As Alvotech Clears Up Legal Overhang

Alvotech and its strategic partner Stada are preparing to launch their higher-strength adalimumab candidate AVT02 in Europe after settling intellectual property disputes with originator AbbVie.

Biosimilars Europe

Avastin, Jevtana And Faslodex Among Stada’s 2021 Complex Offerings

Germany’s Stada completed on several strategic milestones in 2021, including launches, approvals and filings for its burgeoning biosimilars business. Reporting financial results for 2021, Stada disclosed the latest on plans to submit partner Xbrane’s ranibizumab biosimilar with the US FDA.

Sales & Earnings Strategy
See All

Company Information

UsernamePublicRestriction

Register